Bausch Health Companies Inc. (BHC)

NYQ – Real vaqt narxi. Valyuta: USD

5.41

+0.04 (0.74%)

Yopilishda: May 12, 2026, 4:00 PM EDT

5.42

+0.01 (0.18%)

Bozor oldidan: May 13, 2026, 7:20 AM EDT

12.05.2026

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

LAVAL, QC, May 12, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that members of company management will participate in a fireside chat at the Barclays 30th Annual Leveraged Finance Conference in Austin, Texas on Tuesday, May 19, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.

07.05.2026

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced dual-port vitrectomy cutter on the Stellaris Elite® Vision Enhancement System. “The launch of Bi-Blade+ is the latest example of our commitment to delivering meaningful innovation in Europe,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “Stellaris Elite has.

07.05.2026

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Bausch Health delivered a Q1 revenue and net profit beat, but organic growth remains weak and demand is stagnant. BHC's improved margins stem from reduced rebates and discounts, but underlying sales volumes declined, especially in key segments. The investment thesis hinges on deleveraging; if debt is reduced by 20-30%, shares could rise 15-30%, but risks remain high.

01.05.2026

Why Bausch Health Companies Was Crawling Higher This Week

There was notable growth on both the top and bottom lines. The two metrics also topped analyst estimates.

30.04.2026

BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength

Bausch Health posts mixed Q1: EPS misses, but revenues beat estimates on strong Salix and Solta growth. Pipeline progress and the raised 2026 view add momentum.

30.04.2026

Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript

30.04.2026

Bausch Health (BHC) Lags Q1 Earnings Estimates

Bausch Health (BHC) came out with quarterly earnings of $0.78 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.59 per share a year ago.

Videolar

13.11.2025

Positive

Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical

Press-relizlar

12.05.2026

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

07.05.2026

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

29.04.2026

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

First Quarter Consolidated Revenues of $2.52 billion, up 12% on a Reported basis and 7% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health of $1,423 million and GAAP Net Loss of $1,431 million, inclusive of a $1,426 million goodwill impairment charge GAAP Loss per Share of ($3.82) (basic and diluted) compared to ($0.16) in the prior year period Adjusted Earnings per Diluted Share (non-GAAP) of $0.78 compared to $0.59 in the prior year period, an increase of 32% Consolidated Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 of $837 million, up 27% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB FIRST QUARTER 2026 RESULTS Delivered twelfth consecutive quarter of year-over-year Revenue growth and Adjusted EBITDA (non-GAAP)1 growth, with 14% Reported and 9% Organic (non-GAAP)1 Revenue growth and 17% Adjusted EBITDA (non-GAAP)1 growth Generated $319 million in Adjusted Cash Flow from Operations (non-GAAP) 1 Reaffirming full-year 2026 Revenue, Adjusted EBITDA (non-GAAP)1, and Adjusted Cash Flow from Operations (non-GAAP)1 guidance LAVAL, QC, April 29, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2026 financial results and other key updates from the quarter. "Our first quarter performance marks twelve consecutive periods of year‑over‑year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization.

23.04.2026

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Ophthalmology and Therapy published a narrative review highlighting the role of certain B vitamins in reducing the risk of development and progression of AMD1, a leading cause of vision loss in Americans 50 years of age or older.2 Drawing on more than two decades of scientific research, the publication synt.

Bausch Health Companies Inc. (BHC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bausch Health Companies Inc. (BHC)

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Why Bausch Health Companies Was Crawling Higher This Week

BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength

Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript

Bausch Health (BHC) Lags Q1 Earnings Estimates

Videolar

Press-relizlar

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Why Bausch Health Companies Was Crawling Higher This Week

BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength

Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript

Bausch Health (BHC) Lags Q1 Earnings Estimates

Videolar

Press-relizlar

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Search stocks

Bausch Health Companies Inc. (BHC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Bausch Health Companies Inc. (BHC)

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Why Bausch Health Companies Was Crawling Higher This Week

BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength

Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript

Bausch Health (BHC) Lags Q1 Earnings Estimates

Videolar

Press-relizlar

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

Bausch Health: Strong Margins, Weak Volumes, Equity Story Hinges On Deleveraging

Why Bausch Health Companies Was Crawling Higher This Week

BHC Q1 Earnings Miss Estimates, Sales Grow on Salix & Solta Strength

Bausch Health Companies Inc. (BHC) Q1 2026 Earnings Call Transcript

Bausch Health (BHC) Lags Q1 Earnings Estimates

Videolar

Press-relizlar

Bausch Health to Participate in Barclays 30th Annual Leveraged Finance Conference

Bausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in Europe

BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS

Bausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular Degeneration